TRENTON, N.J. (AP) - The U.S. Food and Drug Administration has approved the first drug specifically developed for severe depression after childbirth.
The agency on Tuesday approved Sage Therapeutics' Zulresso (ZUHL'-ress-oh), an IV drug given over 2 ½ days.
In a company-funded study of new mothers with moderate or severe postpartum depression, half the women given Zulresso had depression end within 2 ½ days, about double the rate of those in a comparison group given dummy treatments.
Postpartum depression affects about 400,000 American women a year. It's often treated with antidepressants, though they can take several weeks to help and don't always work.
Sage said Zulresso will cost $34,000 without insurance, plus costs for the stay in a hospital or infusion center.
- FDA approves drug for treating postpartum depression
- FDA approves first postpartum depression drug
- FDA approves medication to help with postpartum depression
- U.S. health officials approve ketamine-like drug for severe depression
- FDA approves preventive migraine treatment
- FDA approves 1st nonopioid drug to ease withdrawal symptoms
- The FDA has five weeks till money runs out for approving new drugs
- FDA approves technology to analyze nutrients in breast milk
- Food and Drug Administration approves new flu drug
- Newly approved FDA cancer treatment to impact patients in the Tennessee Valley